What are the challenges in targeting these biomolecules in cancer?
Despite the potential, there are significant challenges in targeting lipids, proteins, and DNA in cancer. Tumor heterogeneity means that different cells within the same tumor may have varying lipid, protein, and genetic profiles, complicating treatment strategies. Additionally, cancer cells can develop resistance to targeted therapies through various mechanisms, such as mutations in the drug target, activation of alternative signaling pathways, or changes in drug metabolism. Off-target effects and toxicity to normal cells also pose significant hurdles. Thus, a deeper understanding of the molecular mechanisms and the development of combination therapies are essential.
